Skip to content
Screener

BioCryst Pharmaceuticals BCRX Q2 2026 earnings

Reported August 5, 2026 · Before market open

Revenue$218.3MBeat by $35.0M
EPS$0.30Beat by $0.15
Revenue estimate$183.3M
EPS estimate$0.15
“We were pleased to deliver strong revenue growth and positive free cash flow again in the second quarter, reflecting our continued focus on expanding the reach of ORLADEYO while advancing our prioritized pipeline programs. We are especially excited to have begun shipments of the ORLADEYO oral pellet formulation – an important milestone for children living with hereditary angioedema – and we are fully committed to making the launch a success.”
Charlie Gayer

Next report

Nov 2, 2026 (in a month)
Revenue estimate$165.7M
EPS estimate$0.10

Financials

Q2 2026

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$2.07B+34.8%
Enterprise value$2.33B+40.1%
P/S2.2×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%—

Returns & leverage

See full
Current ratio2.3×+0.1×

Segments

By segment

See full
Reportable Segment$218.3M+33.6%

FAQ

When did BioCryst Pharmaceuticals report Q2 2026 earnings?
BioCryst Pharmaceuticals (BCRX) reported Q2 2026 earnings on August 5, 2026 before market open.
What were BioCryst Pharmaceuticals's Q2 2026 revenue and EPS?
BioCryst Pharmaceuticals reported revenue of $218.3M and eps of $0.30 for Q2 2026.
Did BioCryst Pharmaceuticals beat estimates in Q2 2026?
Revenue beat the consensus estimate of $183.3M by $35.0M. EPS beat the consensus estimate of $0.15 by $0.15.
How did BioCryst Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 33.6% from $163.4M a year earlier and eps grew 100.0% from $0.15.
Where can I find BioCryst Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K/A earnings release (0001171843-26-005168) and the 10-Q periodic report (0001628280-26-053300) directly on SEC EDGAR. The filing index links above go to sec.gov.